Oral butyrate for mildly to moderately active Crohn's disease

被引:206
作者
Di Sabatino, A
Morera, R
Ciccocioppo, R
Cazzola, P
Gotti, S
Tinozzi, FP
Tinozzi, S
Corazza, GR
机构
[1] Univ Pavia, IRCCS Policlin San Matteo, Med Clin 1, Dept Med 1, I-27100 Pavia, Italy
[2] Univ Pavia, IRCCS Policlin San Matteo, Dept Surg, I-27100 Pavia, Italy
[3] Promefarm SRL, Dept Med, Milan, Italy
关键词
D O I
10.1111/j.1365-2036.2005.02639.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Butyrate exerts anti-inflammatory effects in experimental colitis and on Crohn's disease lamina propria mononuclear cells in vitro. Aim: To explore the efficacy and safety of oral butyrate in Crohn's disease. Methods: Thirteen patients with mild-moderate ileocolonic Crohn's disease received 4 g/day butyrate as enteric-coated tablets for 8 weeks. Full colonoscopy and ileoscopy were performed before and after treatment. Endoscopical and histological score, laboratory data, Crohn's disease activity index and mucosal interleukin (IL)-1 beta, IL-6, IL-12, interferon-gamma, tumour necrosis factor-alpha and nuclear factor-kappa B (NF-kappa B) were assessed before and after treatment. Results: One patient withdrew from the study, and three patients did not experience clinical improvement. Among the nine patients (69%) who responded to treatment, seven (53%) achieved remission and two had a partial response. Endoscopical and histological score significantly improved after treatment at ileocaecal level (P < 0.05). Leucocyte blood count, erythrocyte sedimentation rate and mucosal levels of NF-kappa B and IL-1 beta significantly decreased after treatment (P < 0.05). Conclusions: Oral butyrate is safe and well tolerated, and may be effective in inducing clinical improvement/remission in Crohn's disease. These data indicate the need for a large investigation to extend the present findings, and suggest that butyrate may exert its action through downregulation of NF-kappa B and IL-1 beta.
引用
收藏
页码:789 / 794
页数:6
相关论文
共 25 条
[1]  
BEST WR, 1976, GASTROENTEROLOGY, V70, P439
[2]   n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids [J].
Bohmig, GA ;
Krieger, PM ;
Saemann, MD ;
Wenhardt, C ;
Pohanka, E ;
Zlabinger, GJ .
IMMUNOLOGY, 1997, 92 (02) :234-243
[3]   Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat [J].
Butzner, JD ;
Parmar, R ;
Bell, CJ ;
Dalal, V .
GUT, 1996, 38 (04) :568-573
[4]   SHORT CHAIN FATTY-ACIDS IN THE HUMAN-COLON [J].
CUMMINGS, JH .
GUT, 1981, 22 (09) :763-779
[5]  
Den Hond E, 1998, GASTROENTEROLOGY, V115, P584
[6]  
*EMEA GUID, CPMPEWP228499270601
[7]   TREATMENT OF DIVERSION COLITIS WITH SHORT-CHAIN FATTY-ACID IRRIGATION [J].
HARIG, JM ;
SOERGEL, KH ;
KOMOROWSKI, RA ;
WOOD, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (01) :23-28
[8]   The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line [J].
Inan, MS ;
Rasoulpour, RJ ;
Yin, L ;
Hubbard, AK ;
Rosenberg, DW ;
Giardina, C .
GASTROENTEROLOGY, 2000, 118 (04) :724-734
[9]  
Klampfer L, 2003, MOL CANCER RES, V1, P855
[10]   Butyrate inhibits NF-κB activation in lamina propria macrophages of patients with ulcerative colitis [J].
Lührs, H ;
Gerke, T ;
Müller, JG ;
Melcher, R ;
Schauber, J ;
Boxberger, F ;
Scheppach, W ;
Menzel, T .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (04) :458-466